Depression Clinical Trials in Columbus

View 10 new treatments for depression near you in Columbus, OH. Every day, Power helps over 527 depression patients connect with leading medical research.

ALTO-300 for Depression

Alto Neuroscience Clinic, Columbus + 1 more

This trial is testing ALTO-300, a new medication, to see if it can make antidepressants work better for patients who are already taking them.

Verified

Recruiting
Phase 2
Est. 4 - 6 Weeks
Adam Savitz, MD, PhD
Study Director

MBCT + IV Ketamine for Depression

Research Clinic, Columbus + 1 more

The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Psilocybin for Major Depressive Disorder - TRD

COMPASS Pathways Clinic, Columbus + 1 more

This trial is testing COMP360, a new treatment for adults who have not responded to other depression treatments. Participants will receive one of three doses of COMP360 along with psychological support. The goal is to see if this combination can help improve their depression symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Seltorexant for Depression

Janssen Clinic, Columbus + 1 more

This trial is testing seltorexant, a new medication, to help people with depression and sleep problems who haven't improved enough with their current antidepressants. Seltorexant works by blocking a brain receptor to help improve sleep and mood.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Aticaprant for Depression

Janssen Clinic, Columbus + 1 more

This trial is testing aticaprant to see if it can help adults with major depressive disorder and anhedonia who haven't responded well to other antidepressants. Aticaprant works by blocking certain receptors in the brain to potentially improve depressive symptoms.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Lumateperone for Major Depressive Disorder

Intra-Cellular Therapies Clinic, Columbus + 1 more

This trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.Show More
Recruiting
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Aticaprant for Depression

Janssen Clinic, Columbus + 1 more

This trial is testing if adding aticaprant to current antidepressants is safe and well-tolerated in people with major depressive disorder. The goal is to see if it can help improve their treatment.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical trial
Study Director

RE104 for Postpartum Depression

Reunion Neuroscience Clinic, Columbus + 1 more

This trial is testing whether a single injection of RE104 can help reduce depression in women who have moderate-to-severe postpartum depression. The goal is to see if this treatment works effectively. The exact way RE104 works isn't detailed, but it likely helps by affecting brain chemicals related to mood.Show More
Recruiting

No Placebo Trial

Phase 2
Est. 5 - 8 Weeks
Jasna Hocevar-Trnka, M.D.
Study Director

Nurse Family Partnership for Pregnancies

Research Clinic, Columbus + 1 more

The goal of this clinical trial is to test the Nurse Family Partnership (NFP) in mothers with previous live births (multiparous or multip individuals). The main aims are: Specific Aim 1-Determine the effectiveness of NFP among multiparous women for reducing maternal morbidity and improving pregnancy outcomes. Specific Aim 2-Determine the effectiveness of NFP among index children (child from pregnancy when mother was enrolled) of multiparous women for improving child outcomes. Specific Aim 3 (Exploratory)-In preparation for a future study of the effects of preventive home-visiting programs on mother-index child-sibling triads, describe siblings (characteristics, role, influence) in the context of nurse home-visiting and evaluate the effectiveness of NFP on outcomes for prior-born siblings younger than 6 years old living in the home, including cognitive development, socioemotional development, and identification and referral to needed services. A supplemental study to this study, led by investigators at Yale and Columbia, includes the following Aims: Aim 1: Test whether the NFP causes variation in DNAm at Glucocorticoid-sensitive sites in infants over the first year of life. Aim 2: Determine whether NFP causes differences in epigenetic age in infants over the first year of life. Aim 3: Evaluate DNAm signatures as predictors of infant development at 12 months of age.Show More
Recruiting

No Placebo Trial

N/A
Est. 3 - 12 Weeks
Deena Chisolm, PhD
Principal Investigator

Mental Health Resiliency Intervention for Suicide Prevention in Nurses

Research Clinic, Columbus + 1 more

The overall purpose of this study is to evaluate the efficacy of an intervention designed to prevent nurse suicide. This randomized controlled trial will test the modified Interactive Screening Program (mISP) alone and the mISP combined with a program called MINDBODYSTRONG. The mISP is a method of screening to detect clinicians at moderate to high risk for suicide and referring them for treatment through an encrypted anonymous on-line platform. MINDBODYSTRONG© is an adaptation of a well-tested cognitive-behavioral skills building intervention (also known as COPE in the literature) that provides a cognitive-behavior theory-based approach to decrease depression, anxiety and suicidal ideation and improve healthy lifestyle beliefs and behaviors in at-risk populations. MINDBODYSTRONG© will involve eight self-paced computerized sessions designed specifically for nurses and clinicians. Nurses will be recruited nationally through the professional nursing organizations and health systems.Show More
Recruiting

No Placebo Trial

N/A
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Page 1 of 2

Frequently Asked Questions

How much do depression clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do depression clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across depression trials in Columbus, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for depression patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Why are others applying to these studies?

  • I have tried two other drugs that didn't have any positive affect on my mental health and am hoping that trying out this trial will help me find a solution.

    M.A. Patient

    Depression Patient

  • I've tried many anti-depressants in my 45 year struggle with Major Depression. I'm hoping this study is the 'game changer'

    B.E. Patient

    Late-Life Depression Patient

  • I've tried more then 5 drugs for depression and it's very depressing frustrating when they do not work, or even help nothing, I'm still looking for that one or 2 that will help

    A.L. Patient

    Major Depression Patient